09:00 | Coffee and Start of Day Two of Summit. |
|
Session Topic: Epigenetic Biomarkers |
| |
09:00 | Development and Validation of DNA Methylation Biomarkers
Andreas Weinhaeusel, Senior Scientist, Austrian Institute of Technology GmbH, Austria
Elucidation of DNA methylation changes is of utmost interest for the development of biomarkers. Along the biomarker developmental chain upon discovery of candidate markers, confirmation and validation are indispensable steps. We have successfully established genome wide screening using Illumina’s bisulfite deamination based 450k human methylation arrays in combination with high throughput-methylation sensitive restriction enzyme (MSRE) coupled qPCR for validation. Therefore we conduct high-throughput analyses of 96 samples x 96 qPCR assays in a single run using 10ng of patient’s DNA. Results from high throughput MSRE-qPCR using were successfully used for efficient confirmation of several panels of 100-200 top-candidate markers and further validation of DNA methylation changes in cancerous and non-cancerous disease. Our established platform combining bisulfite deamination based genome-wide screening and high throughput MSRE -qPCR enables reliable and very efficient validation of DNA methylation markers. |
10:00 | Cellular Immune Monitoring in Clinical Trials using Epigenetic Markers
Ulrich Hoffmueller, Chief Business Officer/Founder, Epiontis GmbH, Germany
|
11:00 | Translating Epigenetic Alterations in Leukemia into Biomarkers of the Disease and for Target Therapies with DNA Demethylating Drugs
Michael Schnekenburger, Team Leader, Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Luxembourg
Aberrant DNA methylation patterns are a common hallmark of tumor cells. We will discuss the translational potential of these epimutations as cancer biomarkers and possible therapeutic strategies related to DNA demethylation. |
12:00 | Lunch, Exhibitor, and Poster Viewing in the ELA2013 Exhibit Hall |
|
Session Topic: microRNA Biomarkers |
| |
13:00 | Exploring microRNA Biomarkers for Non-invasive Diagnosis of Diseases
Markus Beier, Vice President/European Patent Attorney, Comprehensive Biomarker Center GmbH, Germany
Teaming up with clinicians in the fields of cancer, autoimmune, cardiovascular and neuro-degenerative diseases a broad screening on microRNAs derived from blood was conducted. Case studies will be presented to demonstrate the potential of microRNA-biomarkers for use in non-invasive diagnosis of diseases. |
14:00 | MicroRNA Signature for the Prediction of Renal Cell Carcinoma Metastasis and Prognosis
Huiqing Wu, Assistant Professor, City of Hope National Medical Center and Beckman Research Institute, United States of America
This study is to develop and validate a microRNA expression signature for the early prediction of clear cell renal cell carcinoma metastasis and prognosis. |
15:00 | Deregulated Circulating microRNAs in the Blood of Cancer Patients
Heidi Schwarzenbach, Assistant Professor, University Medical Center Hamburg Eppendorf, Germany
In my talk I will introduce our recent data showing that deregulated levels of microRNAs are linked to a particular biology of breast and lung carcinomas favoring progression and metastatic spread. The identified microRNAs may expand our understanding of carcinogenesis and their pathogenic function in human tumors. |
|
Session Topic: Therapeutics Applications--RNAi and microRNA Therapeutics |
| |
16:00 | Lipid-based Nanoparticles and the Future of RNAi Therapeutics
Andrew Miller, Professor, Kings College London, United Kingdom
Lipid-based nanoparticles appear very promising as vectors for the functional delivery of RNAi effectors in vivo and in clinic. Therefore, how can we improve these vector systems further in order to maximize RNAi therapeutic effects using minimal RNAi effector doses? |
17:00 | Key Take-Aways and Closing Themes from the Summit.
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
|
17:30 | Close of Day Two of the Summit. |
